Eli Lilly's (LLY) antibody treatment, in a trial, was shown to cut the risk of COVID-19 by 80% for nursing home residents.
Eli Lilly said the trial of the drug, bamlanivimab, involved 965 participants - 299 nursing home residents and 666 staff members -who tested negative for the coronavirus. They were given either an intravenous infusion of the drug or a placebo.
After eight weeks, the participants who had received bamlanivimab were 57% less likely to develop symptomatic Covid-19 than those who had received the placebo.
Latest Videos From TheStreet and Jim Cramer: